An Open-label Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 Weeks Pegylated Interferon Alfa-2a 40 kD (PEGASYS) Combination Therapy With Ribavirin (Copegus) in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy With Pegylated Interferon and Ribavirin.
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms RelapC
- 31 Aug 2018 Biomarkers information updated
- 29 Aug 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Apr 2008 New trial record.